620 related articles for article (PubMed ID: 18324472)
21. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.
Lund MJ; Butler EN; Hair BY; Ward KC; Andrews JH; Oprea-Ilies G; Bayakly AR; O'Regan RM; Vertino PM; Eley JW
Cancer; 2010 Jun; 116(11):2549-59. PubMed ID: 20336785
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network.
Lin NU; Vanderplas A; Hughes ME; Theriault RL; Edge SB; Wong YN; Blayney DW; Niland JC; Winer EP; Weeks JC
Cancer; 2012 Nov; 118(22):5463-72. PubMed ID: 22544643
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.
Ferguson NL; Bell J; Heidel R; Lee S; Vanmeter S; Duncan L; Munsey B; Panella T; Orucevic A
Breast J; 2013; 19(1):22-30. PubMed ID: 23240985
[TBL] [Abstract][Full Text] [Related]
25. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.
Bauer KR; Brown M; Cress RD; Parise CA; Caggiano V
Cancer; 2007 May; 109(9):1721-8. PubMed ID: 17387718
[TBL] [Abstract][Full Text] [Related]
26. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
[TBL] [Abstract][Full Text] [Related]
27. Breast Cancer Mortality in African-American and Non-Hispanic White Women by Molecular Subtype and Stage at Diagnosis: A Population-Based Study.
Tao L; Gomez SL; Keegan TH; Kurian AW; Clarke CA
Cancer Epidemiol Biomarkers Prev; 2015 Jul; 24(7):1039-45. PubMed ID: 25969506
[TBL] [Abstract][Full Text] [Related]
28. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
29. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study.
Troester MA; Sun X; Allott EH; Geradts J; Cohen SM; Tse CK; Kirk EL; Thorne LB; Mathews M; Li Y; Hu Z; Robinson WR; Hoadley KA; Olopade OI; Reeder-Hayes KE; Earp HS; Olshan AF; Carey LA; Perou CM
J Natl Cancer Inst; 2018 Feb; 110(2):176-82. PubMed ID: 28859290
[TBL] [Abstract][Full Text] [Related]
30. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women.
Stark A; Kapke A; Schultz D; Brown R; Linden M; Raju U
Breast Cancer Res Treat; 2008 Feb; 107(3):405-14. PubMed ID: 17431759
[TBL] [Abstract][Full Text] [Related]
31. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
[TBL] [Abstract][Full Text] [Related]
33. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
Dignam JJ; Wieand K; Johnson KA; Raich P; Anderson SJ; Somkin C; Wickerham DL
Breast Cancer Res Treat; 2006 Jun; 97(3):245-54. PubMed ID: 16331345
[TBL] [Abstract][Full Text] [Related]
34. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
Bauer K; Parise C; Caggiano V
BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
[TBL] [Abstract][Full Text] [Related]
35. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Liu Y; West R; Weber JD; Colditz GA
Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
[TBL] [Abstract][Full Text] [Related]
36. African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.
Jones BA; Kasl SV; Howe CL; Lachman M; Dubrow R; Curnen MM; Soler-Vila H; Beeghly A; Duan F; Owens P
Cancer; 2004 Sep; 101(6):1293-301. PubMed ID: 15368321
[TBL] [Abstract][Full Text] [Related]
37. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.
Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W
Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715
[TBL] [Abstract][Full Text] [Related]
38. The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone.
Campbell EJ; Tesson M; Doogan F; Mohammed ZMA; Mallon E; Edwards J
Br J Cancer; 2016 Oct; 115(8):967-973. PubMed ID: 27657341
[TBL] [Abstract][Full Text] [Related]
39. Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors.
Warner ET; Tamimi RM; Hughes ME; Ottesen RA; Wong YN; Edge SB; Theriault RL; Blayney DW; Niland JC; Winer EP; Weeks JC; Partridge AH
J Clin Oncol; 2015 Jul; 33(20):2254-61. PubMed ID: 25964252
[TBL] [Abstract][Full Text] [Related]
40. Breast Cancer Outcomes as Defined by the Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor-2 in a Multi-ethnic Asian Country.
Subramaniam S; Bhoo-Pathy N; Taib NA; Tan GH; See MH; Jamaris S; Ho GF; Looi LM; Yip CH
World J Surg; 2015 Oct; 39(10):2450-8. PubMed ID: 26138872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
